New pill offers hope for pancreatic cancer patients
A new drug called daraxonrasib has shown promise in reducing tumour size for people with advanced pancreatic cancer during a recent medical trial.
The study involved sixty-one individuals who had received diagnoses for the disease that had spread. Doctors said cancer became undetectable in one out of every twelve patients given the specific medication during testing.
Tumours stopped growing in 90% of the group, while more than 60% saw their tumours shrink or disappear completely. Half of all people diagnosed with this condition die within three months because the survival rate remains extremely low globally.
Patients were followed for an average of eighteen months to see if the cancer would return during this observation period. Some individuals did not see the disease come back during this time, suggesting longer studies are needed to confirm results.
Dr Wungki Park presented these findings at a symposium in Barcelona, noting he had never seen so many tumours vanish in spread cases. He stated the duration of disease control may eventually translate into longer survival for those affected by the illness.
“This is the closest to cure”

